EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Beyond PrEP: The Imperative for an HIV Vaccine to End the Epidemic in Africa

Nicaise Ndembi iD, Morenike O Folayan iD, Anthony Pilorget, Nyanda E Ntinginya iD, Betty Mwesigwa iD, Trevor A Crowell iD, Nyaradzo M Mgodi iD, Jerome H Kim iD

Vaccines · 17.07.2026 · 14 (7) · 627

DOI: 10.3390/vaccines14070627 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Vaccines, online erschienen am 17.07.2026. Verfasst von Nicaise Ndembi und 7 weiteren Autor:innen. Beteiligte Einrichtung: International Vaccine Institute, Africa Regional Office, Nyarugenge, 1 KN 78 St, Kigali P.O. Box 3413, Rwanda. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Walter Reed Army Institute of Research, U.S. National Institute of Allergy and Infectious Diseases, NIH, National Institute for Medical Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The era of highly effective pre-exposure prophylaxis (PrEP) has transformed HIV prevention, yet global HIV incidence remains unacceptably high, particularly in sub-Saharan Africa. While antiretroviral-based prevention is critical, persistent structural barriers to access and adherence highlight the urgent need for a complementary preventive HIV vaccine. In this narrative review and perspective, we argue that scientific progress toward an HIV vaccine must be matched by equally ambitious preparedness investments across three domains: manufacturing and supply chains, clinical trial and regulatory infrastructure, and delivery systems and community engagement. Drawing on lessons from the global rollout of PrEP, post-exposure prophylaxis (PEP), and the COVID-19 pandemic response, we outline a five-pillar strategic roadmap. This roadmap focuses on ensuring that a future HIV vaccine reaches the people who need it most from the moment of regulatory authorization, calling for co-investment in diverse platforms, binding advance market commitments, logistical simulation, and proactive planning for post-licensure effectiveness trials. Preparedness is not secondary to science; it is its essential partner.

Schlagwörter

Stichwörter der Autor:innen

AfricaHIV/AIDSpre-exposure prophylaxispreventionvaccines

Autor:innen und Institutionen

  • International Vaccine Institute, Africa Regional Office, Nyarugenge, 1 KN 78 St, Kigali P.O. Box 3413, Rwanda.
  • Oral Health Initiative, Nigerian Institute of Medical Research, Yaba, Lagos 100001, Nigeria.
  • Department of Child Dental Health, Obafemi Awolowo University, Ile-Ife 22005, Nigeria.
  • Department of Public Health Dentistry, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai 600077, Tamil Nadu, India.
  • Mbeya Medical Research Centre, National Institute for Medical Research, Mbeya P.O. Box 2410, Tanzania.
  • Makerere University Walter Reed Program, Kampala P.O. Box 16524, Uganda.

ORCID-Profile: Nicaise Ndembi, Morenike O Folayan, Nyanda E Ntinginya, Betty Mwesigwa, Trevor A Crowell, Nyaradzo M Mgodi, Jerome H Kim

Förderung

  • Walter Reed Army Institute of Research
  • U.S. National Institute of Allergy and Infectious Diseases, NIH
  • National Institute for Medical Research

Zitieren

APA

Ndembi, N., Folayan, M. O., Pilorget, A., Ntinginya, N. E., Mwesigwa, B., Crowell, T. A., Mgodi, N. M., & Kim, J. H. (2026). Beyond PrEP: The Imperative for an HIV Vaccine to End the Epidemic in Africa. Vaccines, 14(7), 627. https://doi.org/10.3390/vaccines14070627

Vancouver

Ndembi N, Folayan MO, Pilorget A, Ntinginya NE, Mwesigwa B, Crowell TA, et al. Beyond PrEP: The Imperative for an HIV Vaccine to End the Epidemic in Africa. Vaccines. 2026;14(7):627. doi:10.3390/vaccines14070627

BibTeX
@article{Ndembi2026,
  author = {Ndembi, Nicaise and Folayan, Morenike O and Pilorget, Anthony and Ntinginya, Nyanda E and Mwesigwa, Betty and Crowell, Trevor A and Mgodi, Nyaradzo M and Kim, Jerome H},
  title = {Beyond PrEP: The Imperative for an HIV Vaccine to End the Epidemic in Africa},
  journal = {Vaccines},
  year = {2026},
  volume = {14},
  number = {7},
  pages = {627},
  doi = {10.3390/vaccines14070627}
}
Kostenlos starten →